BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.
Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
Planned surgical tumor resection,
No objection to participate in research
Signed genetic consent
Patients under guardianship, curatorship or protective supervision
Taking immunosuppressants
Pregnant or breast-feeding women
Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care
Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
Cohort
Prospective
samples
Other interventionA 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.
Molecular mechanism
Description of the molecular mechanism involved in the progression and recurrence of glioblastoma
Metabolic mechanism
Description of the metabolic mechanism involved in the progression and recurrence of glioblastoma.
Immune mechanism
Description of the immune mechanism involved in the progression and recurrence of glioblastoma
Click on the lead sponsor to view all of their trials.
University Hospital, Bordeaux
Lead sponsor
University of Bordeaux
Collaborator
